miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis-Reference-Cited by-同舟云学术

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis

Published:2014-09-25 Issue:13 Volume:124 Page:e21-e32
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Norfo Ruggiero¹,Zini Roberta¹,Pennucci Valentina¹,Bianchi Elisa¹,Salati Simona¹,Guglielmelli Paola²,Bogani Costanza²,Fanelli Tiziana²,Mannarelli Carmela²,Rosti Vittorio³,Pietra Daniela⁴,Salmoiraghi Silvia⁵,Bisognin Andrea⁶,Ruberti Samantha¹,Rontauroli Sebastiano¹,Sacchi Giorgia¹,Prudente Zelia¹,Barosi Giovanni³,Cazzola Mario⁴,Rambaldi Alessandro⁵,Bortoluzzi Stefania⁶,Ferrari Sergio⁷,Tagliafico Enrico⁷,Vannucchi Alessandro M.²,Manfredini Rossella¹^ORCID

Affiliation:

1. Centre for Regenerative Medicine, Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy;

2. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;

3. Center for the Study of Myelofibrosis, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation, Pavia, Italy;

4. Department of Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy;

5. Hematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy;

6. Department of Biology, University of Padua, Padua, Italy; and

7. Center for Genome Research, Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy

Abstract

Key Points Differential gene and miRNA expression analysis in PMF granulocytes identifies new biomarkers and putative therapeutic targets. Activation of the miR-155/JARID2 axis in PMF CD34+ cells results in overproduction of MK precursors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/13/e21/1380396/e21.pdf

Reference46 articles.

1. Advances in understanding and management of myeloproliferative neoplasms.;Vannucchi;CA Cancer J Clin,2009

2. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.;Tefferi;Leukemia,2008

3. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.;Levine;Cancer Cell,2005

4. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.;Pardanani;Blood,2006

5. New mutations and pathogenesis of myeloproliferative neoplasms.;Vainchenker;Blood,2011

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis;Blood;2024-04-04

2. A let-7 microRNA-RALB axis links the immune properties of iPSC-derived megakaryocytes with platelet producibility;Nature Communications;2024-03-22

3. MiR-155 promotes compensatory lung growth by inhibiting JARID2 activation of CD34+ endothelial progenitor cells;PLOS ONE;2024-02-23

4. miR-217 Regulates Normal and Tumor Cell Fate Following Induction of Endoplasmic Reticulum Stress;Molecular Cancer Research;2024-01-18

5. Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice;Experimental Hematology;2023-12